HR Execs on the Move

Biomet

www.biomet.com

 
Biomet, Inc. is one of the world's leading medical device manufacturers located in the Warsaw, Indiana business cluster. The company specializes in reconstructive products for hips, knees and shoulders, fixation devices, orthopedic support devices, dental implants, spinal implants and operating room supplies.   Biomet was established in 1977 and delivered its first hip replacement in 1978. In a September 2007 club deal the company was acquired by a consortium of private equity firms and ceased trading on NASDAQ.
  • Number of Employees: 1K-5K
  • Annual Revenue: > $1 Billion
  • www.biomet.com
  • 56 E Bell Dr
    Warsaw, IN USA 46582
  • Phone: 574.267.6639

Executives

Name Title Contact Details

Similar Companies

Nipro Diagnostics

Nipro Diagnostics is one of the leading companies in the Healthcare, Pharmaceuticals, & Biotech sector.

Companion Medical

Companion Medical is a leader in the development of advanced technology to improve diabetes care. Companion`s InPen system is available in the U.S. and is the only FDA-cleared, smart insulin pen paired with an integrated diabetes management app.

Wicab

Wicab is a Middleton, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ziehm Medical

Ziehm Medical is a Reno, NV-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

www.biosig.com

BioSig Technologies, Inc. (NASDAQ: BSGM) is a medical device company that is developing a proprietary biomedical signal processing technology platform to address an unmet technology need in the rapidly growing $4.6+ billion electrophysiology (EP) marketplace. Led by a proven management team, world-class Board of Directors and Scientific Advisory Board, Los Angeles-based BioSig Technologies is preparing to commercialize its PURE EP™ System. The PURE EP™System is a surface electrocardiogram (ECG) and intracardiac multichannel recording and analysis system designed to assist electrophysiologists in making crucial clinical decisions in real-time by acquiring and displaying high-fidelity cardiac signal recordings even at undetectable levels (until now) with high accuracy to help identify appropriate catheter ablation targets - areas of tissue to destroy that create a heart rhythm disturbance (arrhythmia). BioSig aims to deliver technology to improve upon catheter ablation treatments for the prevalent and potentially deadly arrhythmias, Atrial Fibrillation and Ventricular Tachycardia. PURE EP™ System is an innovative platform, offering potential benefits over current technologies including increased accuracy, reduced noise and interference, clinical information previously not available and potential elimination of the need for repeat procedures. BioSig has partnered with Minnetronix on technology development and has received FDA 510(k) clearance for the PURE EP™ System in August 2018. BioSig Technologies, Inc. is a Nasdaq company: NASDAQ:BSGM.